Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Unknown × Spironolactone × Clear all

Phase

Phase NA 1 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Recruiting 2 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 1 Hyperandrogenism 1

Interventions

fludarabine 15 Cyclophosphamide 14 Positron Emission Tomography Computed Tomography 4 Gemcitabine 4 68Ga-pentixafor 4 Oncolytic Virotherapy 3 Metformin 3 Melphalan 3 Immunotherapy, Adoptive 3 Cholestanetriol 26-Monooxygenase 3 toripalimab 2 pembrolizumab 2 lenvatinib 2 gallium Ga 68 dotatate 2 fludarabine phosphate 2 alpha-Synuclein 2 Radiotherapy 2 Radiosurgery 2 Pemetrexed 2 Paclitaxel 2 Nivolumab 2 Neoadjuvant Therapy 2 Magnetic Resonance Spectroscopy 2 Influenza Vaccines 2 Fluorodeoxyglucose F18 2 Cisplatin 2 Carboplatin 2 Bevacizumab 2 68Ga-NOTA-RM26 2 68Ga-FAPI 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04075149 2023-10-27

CBS009

University of Virginia

Phase EARLY_PHASE1 Unknown

Polycystic Ovary Syndrome, Hyperandrogenism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡